AST - Asterias Biotherapeutics, Inc.

NYSE American - Nasdaq Real Time Price. Currency in USD
1.28
+0.01 (+0.79%)
At close: 3:57PM EST
Stock chart is not supported by your current browser
Previous Close1.27
Open1.26
Bid0.00 x 800
Ask0.00 x 1800
Day's Range1.22 - 1.30
52 Week Range0.76 - 2.65
Volume353,733
Avg. Volume185,458
Market Cap71.243M
Beta (3Y Monthly)2.04
PE Ratio (TTM)N/A
EPS (TTM)-0.37
Earnings DateNov 12, 2018 - Nov 16, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.88
Trade prices are not sourced from all markets
  • Asterias Biotherapeutics (AST) Reports Q3 Loss, Tops Revenue Estimates
    Zacks12 days ago

    Asterias Biotherapeutics (AST) Reports Q3 Loss, Tops Revenue Estimates

    Asterias Biotherapeutics (AST) delivered earnings and revenue surprises of 20.00% and 10.48%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press12 days ago

    Asterias Biotherapeutics: 3Q Earnings Snapshot

    The Fremont, California-based company said it had a loss of 8 cents per share. The stem cell therapy developer posted revenue of $116,000 in the period. In the final minutes of trading on Friday, the company's ...

  • GlobeNewswire12 days ago

    Asterias Biotherapeutics Reports Third Quarter Results

    Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today reported financial and operational results for the third quarter ended September 30, 2018. On November 7, 2018, Asterias entered into a merger agreement under which Asterias will become a wholly-owned subsidiary of BioTime, Inc. (NYSE American and TASE: BTX) and each outstanding share of common stock of Asterias not already owned by BioTime will be converted into 0.71 common shares of BioTime.  The transaction is expected to close during the Company’s first quarter ending March 31, 2019, subject to the satisfaction of customary closing conditions.

  • GlobeNewswire13 days ago

    Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Asterias Biotherapeutics, Inc. (AST) on Behalf of Stockholders and Encourages AST Investors to Contact the Firm

    NEW YORK, Nov. 08, 2018 -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Asterias Biotherapeutics, Inc. (NYSE: AST) on.

  • ACCESSWIRE13 days ago

    SHAREHOLDER ALERT: WeissLaw LLP Investigates Asterias Biotherapeutics, Inc.

    NEW YORK, NY / ACCESSWIRE / November 8, 2018 / WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Asterias Biotherapeutics, Inc. ...

  • PR Newswire13 days ago

    Wolf Popper LLP Investigates the Proposed Acquisition of Asterias Biotherapeutics, Inc. by BioTime, Inc.

    NEW YORK , Nov. 8, 2018 /PRNewswire/ -- Wolf Popper LLP is investigating claims on behalf of investors in Asterias Biotherapeutics, Inc. (NYSE American: AST) concerning the proposed acquisition of Asterias ...

  • Business Wire13 days ago

    BioTime and Asterias Biotherapeutics Enter Into Definitive Merger Agreement to Create Leading Cell Therapy Company

    BioTime, Inc. (NYSE American and TASE: BTX), and Asterias Biotherapeutics, Inc. (“Asterias”) (NYSE American: AST), today announced that they have entered into a definitive merger agreement whereby BioTime will acquire all of the remaining outstanding common stock of Asterias that are not currently owned by BioTime. Asterias stockholders will receive 0.71 shares of BioTime common shares for every share of Asterias common stock and will own approximately 16.2% of the combined company.

  • Business Wire13 days ago

    BioTime Reports Third Quarter 2018 Financial Results and Provides Business Update

    ALAMEDA, Calif.-- -- Industry Veteran Brian M. Culley Appointed as CEO Signed Agreement to Acquire Asterias Biotherapeutics, Inc. Received $43.2 Million from AgeX Sale Transaction with Juvenescence Ltd. Positive OpRegen® Data Presented at 2018 American Academy of Ophthalmology Annual Meeting Date Set for Distribution of AgeX Therapeutics Shares to BioTime Stockholders BioTime, Inc. , a clinical-stage ...

  • GlobeNewswire19 days ago

    Asterias Biotherapeutics to Report Third Quarter 2018 Results on November 12, 2018

    FREMONT, Calif., Nov. 02, 2018 -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat.

  • GlobeNewswire21 days ago

    Asterias Biotherapeutics Announces Positive Outcome from Data Review from OPC1 Spinal Cord Injury Study

    Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today announced a positive outcome from an independent Data Review Panel’s  review  of the data generated by patients enrolled in the Company’s ongoing Phase 1/2a SCiStar study designed to evaluate the safety and efficacy of OPC1 in the treatment of severe cervical spinal cord injury. Based on a review of the data, the Panel recommended moving forward with the continued clinical development of OPC1.  The next step in the development of OPC1 is a meeting with the Food and Drug Administration (FDA) later this year to discuss proposed next steps for the OPC1 clinical development program, including the trial design for a randomized controlled Phase 2 trial.

  • Simply Wall St.29 days ago

    What Kind Of Shareholders Own Asterias Biotherapeutics Inc (NYSEMKT:AST)?

    Every investor in Asterias Biotherapeutics Inc (NYSEMKT:AST) should be aware of the most powerful shareholder groups. Institutions often own shares in more established companies, while it’s not unusual to see Read More...

  • GlobeNewswire2 months ago

    Asterias Biotherapeutics Announces Facilities and IP License Option Agreements

    FREMONT, Calif., Oct. 01, 2018-- Asterias Biotherapeutics, Inc., a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and ...

  • GlobeNewswire2 months ago

    FDA Accepts Asterias Biotherapeutics’ Request to Meet and Discuss Next Phase of Development for OPC1 Spinal Cord Injury Clinical Program

    Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today announced that the Food and Drug Administration (FDA) has accepted its request to meet to discuss proposed next steps for the OPC1 clinical development program. The Company’s Type B meeting request was made in accordance with the Regenerative Medicine Advanced Therapy (RMAT) designation under the 21st Century Cures Act. The Company is currently completing the ongoing SCiStar trial, an open-label, single-arm trial testing three sequential escalating doses of OPC1 administered at up to 20 million OPC1 cells in 25 subjects with subacute motor complete (AIS-A or AIS-B) cervical (C-4 to C-7) spinal cord injuries (SCI).

  • Simply Wall St.2 months ago

    Healthcare Stocks: Is Now The Time To Buy Asterias Biotherapeutics Inc (NYSEMKT:AST)?

    Asterias Biotherapeutics Inc (NYSEMKT:AST), a US$74.9m small-cap, is a healthcare company operating in an industry, which has experienced tailwinds from issues such as higher demand driven by an aging populationRead More...

  • GlobeNewswire2 months ago

    Asterias Provides 24 Month Cohort 2 Update for its OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury

    Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today provided additional data from the Company’s ongoing Phase 1/2a SCiStar study designed to evaluate the safety and potential efficacy of OPC1 in the treatment of severe cervical spinal cord injury. All 6 subjects from Cohort 2 in the SCiStar study have now completed a 24-month follow-up as part of the study’s long-term follow-up protocol and each subject either retained the motor function recovery seen through 12 months or saw further motor function recovery from 12 to 24 months.

  • GlobeNewswire3 months ago

    Asterias Biotherapeutics Announces Positive Outcome from Second Safety Review Committee Meeting and Open Enrollment for VAC2 Clinical Trial in Non-Small Cell Lung Cancer (NSCLC)

    Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cellular immunotherapies to treat cancer and cell-based therapeutics to treat neurological conditions associated with demyelination, today announced that the Safety Review Committee (SRC) for the first clinical trial of VAC2 has held its second scheduled meeting to review the safety and tolerability data generated in patients two and three enrolled in the study and recommended continuation of the study and moving to open enrollment in the advanced disease cohort (Arm A), as planned per the study’s protocol.

  • Are Options Traders Betting on a Big Move in Asterias Biotherapeutics (AST) Stock?
    Zacks3 months ago

    Are Options Traders Betting on a Big Move in Asterias Biotherapeutics (AST) Stock?

    Investors in Asterias Biotherapeutics (AST) need to pay close attention to the stock based on moves in the options market lately.

  • GlobeNewswire3 months ago

    Asterias Biotherapeutics’ CEO Michael Mulroy to Participate on Regenerative Medicine Therapies Panel at the B. Riley FBR Healthcare Conference

    FREMONT, Calif., Aug. 29, 2018-- Asterias Biotherapeutics, Inc., a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and ...

  • Asterias Biotherapeutics (AST) Reports Q2 Loss, Tops Revenue Estimates
    Zacks3 months ago

    Asterias Biotherapeutics (AST) Reports Q2 Loss, Tops Revenue Estimates

    Asterias Biotherapeutics (AST) delivered earnings and revenue surprises of 0.00% and 3.81%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press3 months ago

    Asterias Biotherapeutics: 2Q Earnings Snapshot

    On a per-share basis, the Fremont, California-based company said it had a loss of 13 cents. Losses, adjusted for non-recurring costs, were 10 cents per share. The results matched Wall Street expectations. ...

  • ACCESSWIRE3 months ago

    Asterias Biotherapeutics Inc Class A to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 9, 2018 / Asterias Biotherapeutics Inc Class A (NYSE American: AST ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 9, 2018 ...

  • Benzinga4 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Netflix, Inc. (NASDAQ: NFLX ) was trading lower by ...